Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: An analysis of the Panama trial (AIO KRK0212).
Authors
Alexej Ballhausen
Department of Hematology, Oncology and Tumorimmunology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;
Alexej Ballhausen , Meinolf Karthaus , Stefan Fruehauf , Ullrich Graeven , Lothar Mueller , Alexander Koenig , Ludwig Fischer von Weikersthal , Greta Sommerhäuser , Annabel Helga Sophie Alig , Eray Goekkurt , Siegfried Haas , Annika Kurreck , Arndt Stahler , Swantje Held , Anke C. Reinacher-Schick , Stefan Kasper , Volker Heinemann , Sebastian Stintzing , Tanja Trarbach , Dominik Paul Modest
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT01991873
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 51)
DOI
10.1200/JCO.2023.41.4_suppl.51
Abstract #
51
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Impact of age and gender on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC): Subgroup analysis of the PANAMA-study (AIO-KRK-0212).
First Author: Kathrin Heinrich
Poster
2016 Gastrointestinal Cancers Symposium
PARADIGM study: A multicenter, randomized, phase III study of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer.
First Author: Takayuki Yoshino
Poster
2023 ASCO Annual Meeting
Impact of number and size of colorectal metastases (CRM) on survival in patients with RAS wild-type metastatic colorectal cancer treated within the PanaMa trial (AIO KRK 0212).
First Author: Greta Sommerhäuser
Poster
2022 ASCO Annual Meeting
Consensus molecular subtypes (CMS) as prognostic and predictive biomarkers of panitumumab (Pmab), fluorouracil and folinic acid (FU/FA) or FU/FA maintenance therapy following Pmab-FOLFOX induction in RAS wildtype metastatic colorectal cancer (mCRC): PANAMA trial (AIO-KRK-0212).
First Author: Beeke Hoppe